title: Analysis of therapeutic effect and safety of target-dose metoprolol in the treatment of patients with diabetes mellitus with chronic heart failure.
abstract: OBJECTIVE
  To explore the therapeutic effect and safety of target-dose metoprolol in treating chronic heart failure (CHF) patients complicated with diabetes mellitus (DM). Method s : One hundred and fifty-four elderly patients were randomly divided into an observation group and a control group (n=77), which were treated with target-dose metoprolol and conventional therapy, and routinely treated respectively. The New York Heart Association (NYHA) classification, left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), 6-min walking distance and medication safety of the two groups were compared.
  
  
  RESULTS
  Compared with the results before treatment, the NYHA classification, LVESD, LVEDD, LVEF and 6-minutes walking distance of both groups were significantly improved (P<0.05), with significantly better results in the observation group than those in the control group after treatment (P<0.05). In the 6 months of follow-up, the incidence of cardiac events in the observation group (3.90%) was significantly lower than that of the control group (14.29%) (P<0.05). The levels of average fasting blood sugar and glycosylated hemoglobin in the groups showed no significant differences (P>0.05).
  
  
  CONCLUSIONS
  Treating CHF patients complicated with DM with target-dose metoprolol can obviously boost the cardiac function and exercise tolerance, leading to satisfactory clinical therapeutic effect, high security and moderate tolerance.
authors.affiliation: Xuyang Liu, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
authors.forename: Xuyang
authors.initials: X
authors.lastname: Liu
authors.affiliation: Chengfu Zhong, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
authors.forename: Chengfu
authors.initials: C
authors.lastname: Zhong
authors.affiliation: Pengtai Zhao, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
authors.forename: Pengtai
authors.initials: P
authors.lastname: Zhao
authors.affiliation: Zhihua Zhang, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
authors.forename: Zhihua
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Ning Jia, Department of Endocrinology, 252 Hospital of PLA, Baoding 071000, P. R. China.
authors.forename: Ning
authors.initials: N
authors.lastname: Jia
authors.affiliation: Sheng'ou Su, Department of Endocrinology, Second Hospital of Hebei Medical University, Shijiazhuang 050000, P. R. China.
authors.forename: Sheng'ou
authors.initials: S
authors.lastname: Su
authors.affiliation: Benliang Zou, Department of Endocrinology, Xiyuan Hospital CACMS, Beijing 010000, P. R. China.
authors.forename: Benliang
authors.initials: B
authors.lastname: Zou
authors.affiliation: Yuming Song, Department of Traditional Chinese Medicine, First Center Hospital of Baoding, Baoding 071000, P. R. China.
authors.forename: Yuming
authors.initials: Y
authors.lastname: Song
keywords: Chronic heart failure; Diabetes mellitus; Metoprolol; Safety; Therapeutic effect